NexoBrid扩展准入项目治疗成人与儿童急性深度烧伤
美国23家烧伤中心开展的单臂扩展准入项目(2019-2024)纳入239例深度热烧伤患者(215成人、24儿童),评估NexoBrid联合标准护理的疗效。成人95%、儿童100%在4小时内完成焦痂清除,无需焦痂切开,安全性与既往试验一致。
要点
- NexoBrid用于成人及儿童深度热烧伤(≤30%体表面积)焦痂清除。
- 成人95%、儿童100%在4小时内完成焦痂清除,无患者需焦痂切开。
- 成人4%需手术切除,儿童无手术切除;中位住院10天。
核心结论
- NexoBrid在扩展准入项目中疗效与既往III期试验相当,可能预防烧伤所致骨筋膜室综合征。
研究设计与样本
- 美国23家烧伤中心单臂扩展准入项目(2019-2024),纳入239例深度热烧伤患者(215成人、24儿童),烧伤面积≤30%体表面积,NexoBrid后标准护理,随访至伤口闭合及3、12个月。
主要发现
- 成人95%、儿童100%在4小时内完成焦痂清除。
- 成人4%行手术切除,儿童无手术切除;无患者需焦痂切开。
- 中位住院时间10天;伤口闭合成人22天、儿童28天。
- 安全性数据与既往试验一致。
关键数值与推荐
- 纳入儿童(<18岁)和成人(≥18岁)深度热烧伤覆盖至多30%总体表面积。
- 142例(131成人、11儿童)完成12个月随访。
- 平均年龄成人41岁、儿童11岁;平均治疗目标创面面积约6%总体表面积,38例环形烧伤。
临床怎么用
- 可对符合条件的成人和儿童深度热烧伤使用NexoBrid进行焦痂清除,减少手术切除需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Following global Phase III trials, a single-arm expanded access program at 23 burn centers in the United States (2019-2024) provided centers with additional experience in treating adult and pediatric burn patients with NexoBrid, and maintaining burn care preparedness for mass casualty incidents. Eligible patients included children (<18-years-old) and adults (≥18-years-old) with deep thermal burns covering up to 30% of the total body surface area. NexoBrid application was followed by standard care. Patients were monitored weekly until wound closure, and again after 3 and 12 months. Outcomes included incidence and time to eschar removal, need for surgical excision or escharotomy, length of hospital stay, wound closure, and Modified Vancouver Scar Scale. A total of 239 patients (215 adult, 24 pediatric) received NexoBrid, with 142 (131 adult, 11 pediatric) completing the 12-month follow-up. Mean ages were 41 and 11 years, respectively. The mean treated target wound area was approximately 6% of the total body surface area, with 38 circumferential burns. Eschar removal was achieved in 95% of adults and 100% of pediatric patients within 4 hours. Surgical excision was performed in 4% of adults, but not in pediatric cases. No escharotomies were needed. The median length of stay was 10 days. Wound closure occurred by 22 days (adults) and 28 days (pediatric). Safety data were consistent with previous trials. NexoBrid demonstrated comparable outcomes vs previous Phase III trials and potential efficacy in preventing burn-induced compartment syndrome.
引用
- Kahn SA, Schulz J, Pham T, et al. An Expanded Access Program With NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries in Adult and Pediatric Patients. J Burn Care Res. 2026. PMID: 42153543. doi:10.1093/jbcr/irag075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。